Skip to main content

Table 1 Clinical characteristics in control subjects and patients with asthma

From: Annexin A1 in plasma from patients with bronchial asthma: its association with lung function

Characteristic

Control subjects

Asthmatic patients

Stable

Exacerbated

No of subjects

25

50

Sex (male/female)

2/23

20/30

Age (of initial visit), yr

58.3 ± 6.2

54.9 ± 14.1

Onset of asthma: age, yr

 

47.06 ± 17.25

Asthma duration, yr

 

6.63 ± 3.60

Smoking status (NS/ES/CS)

25/0/0

32/12/6

Cigarettes smoked, pack. yr

 

9.0 ± 15.7

Body Mass Index, kg/ m2

24.8 ± 2.61

25.4 ± 3.31

Stable and exacerbate lung function

FEV1, % pred.

115.36 ± 16.59

85.43 ± 19.82

62.60 ± 18.14

FVC, % pred.

96.56 ± 14.51

84.83 ± 16.68

66.51 ± 16.76

FEV1 /FVC

84.24 ± 6.05

74.53 ± 9.72

68.07 ± 11.84

PC20, mg/ml

 

9.18 ± 10.37

Total IgE, kU

106.63 ± 188.7

421.5 ± 699.19*

Atopy

1 (4%)

21 (42%)*

Attack average/yr

 

3.38 ± 3.24

Duration of exacerbation during follow up

 

6.63 ± 3.61

Blood WBC/uL

5587.2 ± 1268.0

7768.8 ± 3448.9*

9873.0 ± 4917.1

Blood eosinophil, %

2.73 ± 2.26

5.09 ± 4.97*

3.83 ± 5.42

Blood neutrophil, %

56.25 ± 9.8

54.7 ± 12.9

64.6 ± 19.3

  1. Data expressed as mean ± SD. BMI body mass index, ES ex-smoker, FEV 1 forced expiratory volume in one second, FVC forced vital capacity, NS non-smoker, PC20 methacholine; the concentration of methacholine required to decrease the FEV1 by 20%, SM; smoker. *p < 0.01 compared with control subjects, p < 0.05 compared with stable asthmatics